Navegando por Palavras-chave "Omeprazole"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAssociação entre o uso prolongado de omeprazol e a deficiência de vitamina B12, ferro e magnésio em indivíduos muito idosos independentes(Universidade Federal de São Paulo (UNIFESP), 2021) Didone, Thiago Vinicius Nadaleto [UNIFESP]; Shinohara, Elvira Maria Guerra [UNIFESP]; Universidade Federal de São PauloThe aim of this study was to investigate the association between long-term use of omeprazole and magnesium, vitamin B12 and iron deficiency. Therefore, people aged ≥80 years and functionally independent, participating in the Longevous Project (Discipline of Geriatrics and Gerontology, EPM/UNIFESP), were followed retrospectively for 2 years. Users of stomach acid suppressants, other than omeprazole, and dietary supplements containing the micronutrients of interest, and those with hematological diseases and health conditions that may interfere with the absorption of these micronutrients, were excluded. We obtained primary data, from serum aliquots, and secondary data, from medical record, at baseline (T0) and after 1 (T1) and 2 (T2) years of follow-up. Information on the use of medications was self-reported. The individuals were divided between users (OMP group) and non-users (CTR group) of omeprazole. Levels of the micronutrients of interest (magnesium, vitamin B12, ferritin, transferrin saturation and iron) were quantified in serum samples. Differences in their levels over time were investigated using Friedman's analysis of variance. The accumulated incidence of magnesium deficiency (<0.7mM), vitamin B12 (150ρM) and iron (ferritin <30μg/L) were calculated at T1 and T2. Logistic regression models calculated the odds ratio for the development of deficiency between the OMP and CTR groups. In relation to T0, vitamin B12 levels decreased at T2 both in the OMP (P=.001) and CTR (P=.003) groups; transferrin saturation decreased at T2 only in the OMP group (P=.025). The levels of the other micronutrients did not change over time. The incidence of magnesium, vitamin B12 and iron deficiency did not differ between the OMP and CTR groups at T1 or T2. There was no significant odds ratio between the use of omeprazole and magnesium, vitamin B12 or iron deficiency in T1 or T2. These effect estimates were tested for moderation effects for the following covariates: gender, age, Charlson's comorbidity index, presence of diseases (type 2 diabetes mellitus, neoplasms, thyroid diseases or diseases for which omeprazole use is indicated), kidney function, ultra-sensitive c-reactive protein and the use of medications (diuretics, metformin, non-steroidal anti-inflammatory drugs, antithrombotics, calcium and vitamin D); no moderation effect was found. This work contributes to the understanding of the relationship between the use of proton pump inhibitors and the deficiency of magnesium, vitamin B12 and iron, whose causality remains controversial.
- ItemSomente MetadadadosAvaliação do uso contínuo de inibidores da bomba de prótons na biodisponibilidade de Fe, Ca total e ionizável, Zn, Mg, Cu e K(Universidade Federal de São Paulo (UNIFESP), 2021) Brito, Andrea Santana De [UNIFESP]; Nascimento, Angerson Nogueira do [UNIFESP]; Universidade Federal de São PauloMany studies have shown a relationship between the prolonged use of proton pump inhibitors and the decrease in the bioavailability of several minerals and vitamins, bringing risks to patients using this class of drugs, however, certain relationships are not established. Therefore, this work aimed to evaluate the continuous use of proton pump inhibitors in the bioavailability of Fe, total and ionizable Ca, Zn, Mg, Cu and K. Wistar rats, recently weaned, weighing approximately 200 g, stored in appropriate cage with controlled temperature and humidity. The animals were organized in 2 groups (control and treated) and in subgroups according to the treatment time (10, 30 and 60 days), each subgroup containing 6 rats. The groups were kept at room temperature, with 12-hour cycles (light / dark), under a continuous flow of air; they received feed and water ad libitum, remaining in the same cage until the end of the study according to previous research. Six hours of fasting was performed during the day, immediately before the start of the daily omeprazole administration protocol. The animals at the end of each treatment period were euthanized, their blood and organs collected. Laboratory analysis of physiological (weight), biochemical and hematological parameters and determination of elements using ICP-MS was performed. The results were documented, analyzed and compared. The analyzes were evaluated statistically according to the analysis of variance method (ANOVA) with one and two evaluation criteria. Comparisons were made using the Tukey test. In all analyzes performed, the differences were considered significant when p˂ 0.05. In conjunction with the analysis of variance, effects size was used to examine the difference in means. The results found in this study confirmed that omeprazole may decrease some nutrients present in the diet of rats such as Fe and may cause hematological variations such as those found in hematological cell values such as leukocytes: monocytes, lymphocytes, neutrophils, in addition to decreasing hemoglobin and also affect the platelet count. These hematological changes may suggest a decrease in the immunity of the rats and in blood clotting and anemia.
- ItemAcesso aberto (Open Access)EFEITO DA RANITIDINA E DO OMEPRAZOL SOBRE O pH GÁSTRICO EM CÃES(Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia, 1999-01-01) Abrahão, Silvio; Goldenberg, Saul [UNIFESP]; Goldenberg, Alberto [UNIFESP]; Novo, Neil Ferreira [UNIFESP]; Juliano, Yara [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)The aim of this work was the ranitidine and omeprazole gastric pH effect investigation. 24 adults, male, mongrel dogs were distributed in 3 groups: group A - control, group B - ranitidine and group C - omeprazole. Gastric pH was measured after gastric juice syringe collection in dogs submitted to gastrotomy. Control group measurements were done at times zero, 30, 60, 90 and 120 minutes. Ranitidine group measurements were done at time zero, followed by 0,85 mg/kg endovenous ranitidine, and also at times 30, 60, 90 and 120 minutes. Omeprazole group measurements were done at time zero, followed by 0,68 mg/kg endovenous omeprazole and also at times 30, 60, 90 and 120 minutes.A significant increase in gastric pH, was observed, comparing groups, after ranitidine and omeprazole use. However, ranitidine and omeprazole compared effects presented no significant differences in pH variation.
- ItemAcesso aberto (Open Access)Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents(Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia - IBEPEGE Colégio Brasileiro de Cirurgia Digestiva - CBCD Sociedade Brasileira de Motilidade Digestiva - SBMD Federação Brasileira de Gastroenterologia - FBGSociedade Brasileira de Hepatologia - SBHSociedade Brasileira de Endoscopia Digestiva - SOBED, 2001-09-01) Kawakami, Elisabete [UNIFESP]; Ogata, Silvio Kazuo [UNIFESP]; Miranda, Áurea Cristina Portorreal [UNIFESP]; Magni, Ana Maria; Pardo, Mário Luís E. [UNIFESP]; Patricio, Francy Reis da Silva [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Santa Casa de São Paulo Faculdade de Medicina Division of Pediatric GastroenterologyBackground Helicobacter pylori infection presents high prevalence in developing countries, but there are few pediatric assays evaluating antimicrobial treatment. Objective - The aim of this study was to investigate Helicobacter pylori eradication rate using a short regimen (7 and 10 days) of triple therapy with clarithromycin, amoxicillin and omeprazole. Patients and methods - Twenty-five Hp positive patients who presented severe epigastralgia, were submitted to antimicrobial treatment with amoxicillin (50 mg/kg/day - maximum dose 1g bid), clarithromycin (30 mg/kg/day - maximum dose 500 mg bid) and omeprazole (0.6 mg/kg/day - maximum dose 20 mg bid) during 7 or 10 days. After 2 months, clinical symptoms were evaluated and gastric biopsies were taken to test Hp eradication. Results - Overall eradication rate was achieved in 16/25 patients (64% - IC(95%) = 45-83%), in 11/15 (73% - IC(95%) = 51-95%) patients who used 10 days therapy course and in 5/10 (50% - IC(95%) = 19-81%) who used 7 days therapy course. Eradication drugs were well accepted and adverse effects were reported in two patients (8%). Conclusions - This triple therapy regimen had moderate efficacy (64%). The data suggests that 10 days therapy course achieves better eradication rate (73%) than 7 days course (50%) to treat Hp infection in our population.